Insights - Selecta provided an update this morning for their dose escalating trial for the co-administration of: 1. 0.125mg/kg of SVP-rapamycin + 0.4mg/kg of pegsiticase 2. 0.15 … Continue Reading
Read nowInsights - SWK Holdings (SWKH) announced Q4 and full year 2017 earnings earlier this week and the company is continuing to execute on their business. We initially discussed SWK … Continue Reading
PremiumInsights - Selecta held a conference call to discuss their Q4 2017 results and provided a corporate update. Overall, we believe the call was positive and shed light … Continue Reading
PremiumInsights - On March 20th, 2018 SlingShot Insights hosted a KOL call with Dr. Dr Gail Kerr – MD, discussing Selecta (SELB) candidate SEL-212 and Krystexxa, the … Continue Reading
PremiumInsights - This morning, Fennec (FENC) announced that the FDA had granted the company’s candidate, Pedmark, Breakthrough Therapy Designation for the prevention of cisplatin-related ototoxicity in pediatric patients with … Continue Reading
Read nowInterviews - Operator: Thank you for holding. Welcome to the Selecta Biosciences fourth quarter and year end 2017 conference call. Currently all participants are in a listen … Continue Reading
Read now
